Author:
Alcaraz Antonio,Rodríguez-Antolín Alfredo,Carballido-Rodríguez Joaquín,Castro-Díaz David,Medina-Polo José,Fernández-Gómez Jesús M.,Ficarra Vincenzo,Palou Joan,Ponce de León Roca Javier,Angulo Javier C.,Esteban-Fuertes Manuel,Cózar-Olmo José M.,Pérez-León Noemí,Molero-García José M.,Fernández-Pro Ledesma Antonio,Brenes-Bermúdez Francisco J.,Manasanch José
Abstract
AbstractIn a subset analysis of data from a 6-month, multicenter, non-interventional study, we compared change in symptoms and quality of life (QoL), and treatment tolerability, in men with moderate to severe lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) receiving tamsulosin (TAM, 0.4 mg/day) or the hexanic extract of Serenoa repens (HESr, 320 mg/day) as monotherapy. Symptoms and QoL were assessed using the IPSS and BII questionnaires, respectively. Patients in the treatment groups were matched using two statistical approaches (iterative and propensity score matching). Within the iterative matching approach, data was available from a total of 737 patients (353 TAM, 384 HESr). After 6 months, IPSS scores improved by a mean (SD) of 5.0 (4.3) points in the TAM group and 4.5 (4.7) points in the HESr group (p = 0.117, not significant). Improvements in QoL were equivalent in the two groups. TAM patients reported significantly more adverse effects than HESr patients (14.7% vs 2.1%; p < 0.001), particularly ejaculation dysfunction and orthostatic hypotension. These results show that HESr is a valid treatment option for men with moderate/severe LUTS/BPH; improvements in urinary symptoms and QoL were similar to those observed for tamsulosin, but with considerably fewer adverse effects.
Funder
Pierre Fabre Ibérica S.A.
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. Gravas, S. et al. EAU guidelines on management of non-neurogenic male LUTS including benign prostatic obstruction. Available online: https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Non-Neurogenic-Male-LUTS-incl.-BPO-2020.pdf (2020) (accessed on 29 March 2021).
2. Ng, M., Baradhi, K.M. Benign prostatic hyperplasia. [Updated 2020 Aug 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, Jan. https://www.ncbi.nlm.nih.gov/books/NBK558920/ (2020). https://www.ncbi.nlm.nih.gov/books/NBK558920/
3. Roehrborn, C. G. Benign prostatic hyperplasia: an overview. Rev. Urol. 7(Suppl 9), S3–S14 (2005).
4. Speakman, M., Kirby, R., Doyle, S. & Ioannou, C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK. BJU Int. 115, 508–519 (2015).
5. Peters, T. J. et al. The International Continence Society “Benign Prostatic Hyperplasia” Study: the bothersomeness of urinary symptoms. J. Urol. 157, 885–889 (1997).
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献